Investors-Gan & Lee

中文站

Careers | Investors | Patients and HCPS | Contact us

Careers Investors Patients and HCPS Contact us

Search

# Popular search #

Diabetes Oncology Medical Devices

Investors

Investors Financial Reports IR Appointment

FY2025 Q3 Financial Performance Overview

Operating Income (CNY)

3.047Billion
Increase by 35.7% YOY
Net Profit Attributable Parent (CNY)

818 Million
Increase by 61.3% YOY
Sales Income in China (CNY)

2.690Billion
Increase by 44.0% YOY
International Income (CNY)

353Million
Increase by 45.5% YOY
R&D Input Ratio (R&D Input/Operating Income)

29.0%
R&D Investment 883 Million CNY
Equity Incentive(Around 87 Employees Granted)

7.04 Million
Shares of Restricted Stock Total Shares before the Grant of the Company 1.1849%

Our websites

Gangan Technology

You are now leaving the Gan & Lee website.

The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.

Continue Back

Search

Operating Income (CNY)

Net Profit Attributable Parent (CNY)

Sales Income in China (CNY)

International Income (CNY)

R&D Input Ratio (R&D Input/Operating Income)

Equity Incentive(Around 87 Employees Granted)

Subscribe